REGULATED PRESS RELEASE
News
-
-
PRESS RELEASE
Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet
Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet. The publication highlights the positive results of Sarconeos (BIO101) in reducing the risk of death or respiratory failure in adults hospitalized with severe respiratory symptoms due to COVID-19. Biophytis will also host press conferences to discuss the potential and clinical benefits of Sarconeos (BIO101) in severe forms of COVID-19 and its exploration in the treatment of other respiratory viral infections. For more information, visit www.biophytis.com -
PRESS RELEASE
Biophytis announces the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract
Biophytis, a clinical-stage biotechnology company focused on developing therapeutics for age-related diseases, has announced the drawing of the fourth tranche of its convertible bond agreement with Atlas, a specialized investment fund based in New York. This tranche consists of 80 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) with a total value of €4 million. The ORNANE have a 24-month maturity period and do not bear interest. Holders have the option -
PRESS RELEASE
Biophytis to attend BIO-Europe in Munich
-
-
-
-
-
-
